Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
about
An enzymatically activated fluorescence probe for targeted tumor imaging.Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers.Towards a ligand targeted enzyme prodrug therapy: single round panning of a beta-lactamase scaffold library on human cancer cells.Developing bifunctional beta-lactamase molecules with built-in target-recognizing module for prodrug therapy: identification of Enterobacter Cloacae P99 cephalosporinase loops suitable for randomization and phage-display selection.Novel beta-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapyRecent trends in targeted anticancer prodrug and conjugate design.Biodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model.Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease TherapyMethotrexate: a detailed review on drug delivery and clinical aspects.Aziridines: epoxides' ugly cousins?Monoclonal antibody therapeutics and apoptosis.Optical imaging of targeted β-galactosidase in brain tumors to detect EGFR levelsChemical approaches to the discovery and development of cancer therapies.Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities.Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.Antitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminaseCAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.Antibody-enzyme fusion proteins for cancer therapy.Novel therapy based on camelid nanobodies.Targeted prodrug approaches for hormone refractory prostate cancer.An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy.The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.Bispecific antibody complex pre-targeted delivery of polymer-drug conjugates for cancer therapy.Nanoengineered polymer capsules: tools for detection, controlled delivery, and site-specific manipulation.An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation.Diethylstilbestrol glutamate as a potential substrate for ADEPT.
P2860
Q30483794-60C283E5-9511-46B3-8C0D-6B887306C339Q33235069-48FE0756-5F7F-427D-9127-05F3580C7FB0Q33272567-CD5934AD-B095-4A5C-9BF6-531F3BCFD151Q33444939-96E799FD-CC8E-46F4-A151-E511325D8AE0Q33502835-B269787E-D83E-4326-A4CC-C78314E9DAB1Q33573762-F1A7722C-3B39-47B0-B650-EDE6BCA7942BQ33625341-C07C1F7E-1069-4A98-B986-A4574E421169Q33834772-7509015D-E503-4D61-8A55-7E5A2383D7A0Q34247680-A1A3EB40-AB56-4B14-9094-2C58C53A9C21Q34927122-8852A58D-1046-454C-9544-BA27CECD5707Q35603396-E6835D5B-138F-484D-B2CC-BBAE78CBDE6DQ35624259-B7325482-BE00-4733-B7B0-215A5472F486Q36085630-FDBA61F8-D2C1-42CE-967C-C776DA7FE2A8Q36167027-AC482D2E-8954-41E7-8B90-B464C62B494DQ36883720-29180AEB-15C2-42F7-A27E-DF47D8D536AAQ37251338-87D89D2F-1602-4739-8207-8EF52275F848Q37342767-C7643CEE-4CB6-497A-9CE0-DDF5A07A827CQ37842324-65BD5266-E6D2-40CA-8CF8-2CB82E7C876DQ38151739-F5456F87-FA8A-4ECE-96D3-9D214E5CA234Q38295983-F8B60822-A155-47C7-96FB-3DBC9806833DQ38741706-37DE191D-CA07-43B0-B0E7-F42E76AF3D49Q39274501-8ABE1510-A45C-4A99-A133-74A2A588E001Q39402193-E7B3EDEE-3E21-4850-9D6C-59EAB3128ED1Q39404483-4E8CDC32-B559-4196-B055-A7B776FFA412Q51090626-5A6B152D-D4D0-41DB-B614-EA394F260003Q53197611-52C8E420-D716-474F-B284-70610CCCBF64Q53589248-3016E02C-3EF4-40D7-A228-9135D6A5D29E
P2860
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
@ast
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
@en
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
@nl
type
label
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
@ast
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
@en
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
@nl
prefLabel
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
@ast
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
@en
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
@nl
P1476
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
@en
P2093
Springer CJ
P304
P356
10.1016/S0169-409X(01)00206-X
P407
P577
2001-12-01T00:00:00Z